According to a new report from Intel Market Research, the global Tocilizumab Biosimilars market was valued at USD 1.45 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 9.7% during the forecast period (2026-2034). This significant growth is driven by the increasing prevalence of autoimmune diseases, cost...